These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 15054809

  • 1. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease.
    Ruiz-Argüelles GJ, Rangel JD, Ponce-de-León S, González-Déctor L, Reyes-Núñez V, Garcés-Eisele J.
    Am J Hematol; 2004 Apr; 75(4):200-4. PubMed ID: 15054809
    [Abstract] [Full Text] [Related]

  • 2. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
    Nachbaur D, Larcher C, Kircher B, Eibl G, Nussbaumer W, Gunsilius E, Haun M, Grünewald K, Gastl G.
    Ann Hematol; 2003 Oct; 82(10):621-7. PubMed ID: 12920570
    [Abstract] [Full Text] [Related]

  • 3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, Bacigalupo A.
    Haematologica; 1998 Feb 01; 83(2):132-7. PubMed ID: 9549924
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL, Martino R, Barba P, Margall N, Roig MC, Valcárcel D, Sierra J, Rabella N.
    Bone Marrow Transplant; 2010 Mar 01; 45(3):534-42. PubMed ID: 19668235
    [Abstract] [Full Text] [Related]

  • 6. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V, Ugur A, Colak D, Saba R, Tezcan G, Kupesiz A, Karadogan I, Gultekin M, Yesilipek A, Undar L.
    Jpn J Infect Dis; 2006 Aug 01; 59(4):216-21. PubMed ID: 16936338
    [Abstract] [Full Text] [Related]

  • 7. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2009 Jun 01; 15(6):679-85. PubMed ID: 19450752
    [Abstract] [Full Text] [Related]

  • 8. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
    Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K, Hensel N, Childs R, Barrett AJ.
    Biol Blood Marrow Transplant; 2004 Jan 01; 10(1):49-57. PubMed ID: 14752779
    [Abstract] [Full Text] [Related]

  • 9. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
    George B, Kerridge I, Gilroy N, Huang G, Hertzberg M, Gottlieb D, Bradstock K.
    Bone Marrow Transplant; 2010 May 01; 45(5):849-55. PubMed ID: 19915635
    [Abstract] [Full Text] [Related]

  • 10. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS.
    Pediatr Blood Cancer; 2007 Sep 01; 49(3):306-12. PubMed ID: 16972242
    [Abstract] [Full Text] [Related]

  • 11. Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Reddy V, Meier-Kriesche HU, Greene S, Schold JD, Wingard JR.
    Biol Blood Marrow Transplant; 2005 Sep 01; 11(9):698-705. PubMed ID: 16125640
    [Abstract] [Full Text] [Related]

  • 12. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
    Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE, Brenner MK, Popat U.
    Bone Marrow Transplant; 2005 Nov 01; 36(9):797-802. PubMed ID: 16151431
    [Abstract] [Full Text] [Related]

  • 13. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group.
    George B, Kerridge IH, Gilroy N, Huang G, Hertzberg MS, Bradstock KF, Gottlieb DJ.
    Transpl Infect Dis; 2012 Apr 01; 14(2):141-8. PubMed ID: 22283838
    [Abstract] [Full Text] [Related]

  • 14. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.
    Jaskula E, Dlubek D, Duda D, Bogunia-Kubik K, Mlynarczewska A, Lange A.
    Biol Blood Marrow Transplant; 2009 Oct 01; 15(10):1296-305. PubMed ID: 19747638
    [Abstract] [Full Text] [Related]

  • 15. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.
    Avetisyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljungman P.
    Bone Marrow Transplant; 2006 Nov 01; 38(10):687-92. PubMed ID: 17001346
    [Abstract] [Full Text] [Related]

  • 16. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
    Liu YC, Lu PL, Hsiao HH, Chang CS, Liu TC, Yang WC, Lin SF.
    Ann Hematol; 2012 Apr 01; 91(4):587-95. PubMed ID: 21997849
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen.
    Mohty M, Mohty AM, Blaise D, Faucher C, Bilger K, Isnardon D, Sainty D, Gastaut JA, Viens P, Olive D, Gaugler B.
    Bone Marrow Transplant; 2004 Apr 01; 33(8):839-46. PubMed ID: 14767500
    [Abstract] [Full Text] [Related]

  • 18. A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients.
    Tsirigotis P, Bitan RO, Resnick IB, Samuel S, Ackerstein A, Eladì S, Gesundheit B, Zilberman I, Miron S, Leubovic A, Slavin S, Shapira MY.
    Haematologica; 2006 Jun 01; 91(6):852-5. PubMed ID: 16769592
    [Abstract] [Full Text] [Related]

  • 19. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning.
    Kalpoe JS, van der Heiden PL, Vaessen N, Claas EC, Barge RM, Kroes AC.
    Bone Marrow Transplant; 2007 Jul 01; 40(2):137-43. PubMed ID: 17530007
    [Abstract] [Full Text] [Related]

  • 20. Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT.
    Scholl S, Mügge LO, Issa MC, Kasper C, Pachmann K, Höffken K, Sayer HG.
    Bone Marrow Transplant; 2005 Jan 01; 35(2):183-90. PubMed ID: 15531897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.